IBIO Relative Valuation
IBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IBIO is overvalued; if below, it's undervalued.
Historical Valuation
iBio Inc (IBIO) is now in the Fair zone, suggesting that its current forward PS ratio of 605.66 is considered Fairly compared with the five-year average of -4.08. The fair price of iBio Inc (IBIO) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：2.23
Fair
-6.38
PE
1Y
3Y
5Y
0.00
EV/EBITDA
iBio Inc. (IBIO) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
0.03
EV/EBIT
iBio Inc. (IBIO) has a current EV/EBIT of 0.03. The 5-year average EV/EBIT is -1.95. The thresholds are as follows: Strongly Undervalued below -6.65, Undervalued between -6.65 and -4.30, Fairly Valued between 0.40 and -4.30, Overvalued between 0.40 and 2.75, and Strongly Overvalued above 2.75. The current Forward EV/EBIT of 0.03 falls within the Historic Trend Line -Fairly Valued range.
605.66
PS
iBio Inc. (IBIO) has a current PS of 605.66. The 5-year average PS is 92.45. The thresholds are as follows: Strongly Undervalued below -154.36, Undervalued between -154.36 and -30.95, Fairly Valued between 215.85 and -30.95, Overvalued between 215.85 and 339.25, and Strongly Overvalued above 339.25. The current Forward PS of 605.66 falls within the Strongly Overvalued range.
-2.02
P/OCF
iBio Inc. (IBIO) has a current P/OCF of -2.02. The 5-year average P/OCF is -0.38. The thresholds are as follows: Strongly Undervalued below -2.50, Undervalued between -2.50 and -1.44, Fairly Valued between 0.68 and -1.44, Overvalued between 0.68 and 1.74, and Strongly Overvalued above 1.74. The current Forward P/OCF of -2.02 falls within the Undervalued range.
-1.64
P/FCF
iBio Inc. (IBIO) has a current P/FCF of -1.64. The 5-year average P/FCF is -0.21. The thresholds are as follows: Strongly Undervalued below -1.35, Undervalued between -1.35 and -0.78, Fairly Valued between 0.35 and -0.78, Overvalued between 0.35 and 0.92, and Strongly Overvalued above 0.92. The current Forward P/FCF of -1.64 falls within the Strongly Undervalued range.
iBio Inc (IBIO) has a current Price-to-Book (P/B) ratio of 0.73. Compared to its 3-year average P/B ratio of 0.87 , the current P/B ratio is approximately -16.53% higher. Relative to its 5-year average P/B ratio of 1.21, the current P/B ratio is about -39.48% higher. iBio Inc (IBIO) has a Forward Free Cash Flow (FCF) yield of approximately -38.09%. Compared to its 3-year average FCF yield of -247.59%, the current FCF yield is approximately -84.62% lower. Relative to its 5-year average FCF yield of -186.84% , the current FCF yield is about -79.61% lower.
0.73
P/B
Median3y
0.87
Median5y
1.21
-38.09
FCF Yield
Median3y
-247.59
Median5y
-186.84
Competitors Valuation Multiple
The average P/S ratio for IBIO's competitors is 101.02, providing a benchmark for relative valuation. iBio Inc Corp (IBIO) exhibits a P/S ratio of 605.66, which is 499.57% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of IBIO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of IBIO in the past 1 year is driven by Unknown.
People Also Watch
NXGL
Nexgel Inc
1.72USD
-2.27%
MRKR
Marker Therapeutics Inc
2.19USD
17.74%
HYFM
Hydrofarm Holdings Group Inc
1.925USD
-11.70%
PZG
Paramount Gold Nevada Corp
1.14USD
2.70%
CTRM
Castor Maritime Inc
2.14USD
-0.47%
IPW
iPower Inc
7.4348USD
-1.52%
CREX
Creative Realities Inc
3.12USD
11.83%
IGC
IGC Pharma Inc
0.3075USD
6.57%
CPSH
CPS Technologies Corp
3.16USD
-0.94%
Frequently Asked Questions
Is iBio Inc (IBIO) currently overvalued or undervalued?
iBio Inc (IBIO) is now in the Fair zone, suggesting that its current forward PS ratio of 605.66 is considered Fairly compared with the five-year average of -4.08. The fair price of iBio Inc (IBIO) is between to according to relative valuation methord.
What is iBio Inc (IBIO) fair value?
IBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of iBio Inc (IBIO) is between to according to relative valuation methord.
How does IBIO's valuation metrics compare to the industry average?
The average P/S ratio for IBIO's competitors is 101.02, providing a benchmark for relative valuation. iBio Inc Corp (IBIO) exhibits a P/S ratio of 605.66, which is 499.57% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for iBio Inc (IBIO) as of Jan 08 2026?
As of Jan 08 2026, iBio Inc (IBIO) has a P/B ratio of 0.73. This indicates that the market values IBIO at 0.73 times its book value.
What is the current FCF Yield for iBio Inc (IBIO) as of Jan 08 2026?
As of Jan 08 2026, iBio Inc (IBIO) has a FCF Yield of -38.09%. This means that for every dollar of iBio Inc’s market capitalization, the company generates -38.09 cents in free cash flow.
What is the current Forward P/E ratio for iBio Inc (IBIO) as of Jan 08 2026?
As of Jan 08 2026, iBio Inc (IBIO) has a Forward P/E ratio of -6.38. This means the market is willing to pay $-6.38 for every dollar of iBio Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for iBio Inc (IBIO) as of Jan 08 2026?
As of Jan 08 2026, iBio Inc (IBIO) has a Forward P/S ratio of 605.66. This means the market is valuing IBIO at $605.66 for every dollar of expected revenue over the next 12 months.